Humacyte, Inc. filings document a commercial-stage biotechnology issuer built around acellular tissue engineered vessels and related bioengineered human tissue programs. Its reports and 8-K filings cover operating results, product commercialization, clinical and regulatory disclosures, material agreements for Symvess distribution rights, and collaboration or licensing arrangements.
The company’s SEC record also includes capital-structure disclosures for common stock and redeemable warrants, equity offering arrangements, secured debt financing, and Nasdaq listing-rule notices. Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and other governance disclosures for HUMA.
Humacyte, Inc. reported that President and CEO Laura E. Niklason had an indirect acquisition of stock options through her spouse. The grant covers 80,000 stock options for Humacyte common stock at an exercise price of $1.08 per share, expiring on June 11, 2036. According to the vesting schedule, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments on the 11th of each month through June 11, 2030.
Humacyte, Inc. director Kathleen Sebelius reported a grant of stock options representing the right to buy 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments on the 11th of each month through June 11, 2030. Following this grant, Sebelius holds 80,000 stock options directly.
Humacyte, Inc. director Keith Anthony Jones received a grant of stock options for 80,000 shares of Common Stock. The options were awarded at an exercise price of $1.08 per share and are held directly. Following the grant, Jones holds 80,000 stock options.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027. After that date, 1/48 of the option vests on the 11th of each month through June 11, 2030, with the option expiring on June 11, 2036. This is a compensation-related award rather than an open-market purchase or sale.
Humacyte, Inc. director Charles Bruce Green received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds 80,000 stock options directly.
According to the vesting terms, the first 25% of the option becomes exercisable on June 11, 2027, and the remaining portion vests in equal monthly installments through June 11, 2030. This is a compensation-related award rather than an open-market share purchase or sale.
Humacyte director Diane Seimetz received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. This is a compensation-related award, not an open-market purchase. Following the grant, she holds options on 80,000 shares directly. The footnote states that 25% of the options vest on June 11, 2027, with the remainder vesting in equal monthly installments through June 11, 2030.
Humacyte, Inc. reported that director John Philip Bamforth received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. Following this grant, he holds 80,000 options directly.
The footnote explains that 25% of the options become exercisable on June 11, 2027, with the remaining portion vesting in equal monthly installments (1/48 of the grant) on the 11th of each month through June 11, 2030. This is a compensation-related award rather than an open-market purchase.
Humacyte, Inc. director Emery N. Brown received a grant of stock options covering 80,000 shares of common stock at an exercise price of 1.08 per share. The options expire on June 11, 2036. One quarter vests on June 11, 2027, with the remainder vesting monthly through June 11, 2030.
Humacyte, Inc. director Brady W. Dougan received a grant of stock options to acquire common shares. The award covers options exercisable for 80,000 shares of Humacyte common stock at an exercise price of $1.08 per share, expiring on June 11, 2036.
The options were granted as compensation and do not reflect an open-market purchase or sale. According to the vesting terms, 25% of the options become exercisable on June 11, 2027, with the remaining options vesting in equal monthly installments through June 11, 2030.
Humacyte, Inc. entered into an underwriting agreement for a public offering of its common stock. The company is issuing 47,619,048 shares at a public offering price of $1.05 per share, with underwriters holding a 30‑day option to buy up to 7,142,857 additional shares.
Gross proceeds are expected to be $50 million, with net proceeds of about $46.80 million, or $53.85 million if the option is fully exercised. Humacyte plans to use the cash to commercialize its Symvess product, support a planned Biologics License Application supplement in a hemodialysis indication, advance its pipeline, and for working capital and general corporate purposes.
Humacyte, Inc. is offering 47,619,048 shares of its common stock pursuant to this prospectus supplement, at a public offering price of $1.05 per share (underwriters have a 30‑day option to purchase an additional 7,142,857 shares). The offering's gross proceeds are stated as $50,000,000.40, with estimated net proceeds to the company of approximately $47.0 million before expenses (approximately $53.85 million if the underwriters fully exercise their option).
The company reports that shares outstanding after the offering would be 269,638,156 (or 276,781,013 if the option is fully exercised). The prospectus supplement also discloses recently announced positive top-line interim results from the V012 Phase 3 trial, meeting its primary endpoint, and states an intention to submit a supplemental BLA in the second half of 2026. The company notes substantial doubt about its ability to continue as a going concern absent additional financing.